The EGFR instructs complex cellular programs by generating robust signals of defined strength and duration. To preserve signal identity and guard cells against the oncogenic risk generated by unabated signaling, it is imperative that EGFR be tightly regulated. In this framework, the ligand-dependent transition of EGFR from an inactive state to a catalytically competent one is regarded as a key control step. In absence of ligand, the EGFR adopts a default auto-inhibited conformation that is relieved by EGF binding and attendant stabilization of EGFR dimers. These structural transitions result in allosteric activation of the EGFR tyrosine kinase domain (TKD) through formation of asymmetric dimers between juxtaposed TKDs. Downstream signaling is then initiated via in trans phosphorylation of Tyr residues located in the COOH tail of dimerized receptors (Lemmon et al., 2014) . Hence, EGFR activation is essentially driven by ligand: receptor binding kinetics and conformational changes caused by receptor dimerization. A study published in Cell (Bill et al., 2010) expanded this model, suggesting a novel layer of intracellular EGFR regulation implemented by cytohesins.
The cytohesin (CYTH) family includes four members, which are well known guanyl nucleotide exchange factors (GEF) for ARF GTPases (Casanova, 2007) . Through work mainly focused on ARNO, i.e., CYTH2, Bill et al. proposed that cytohesins facilitate allosteric activation of the EGFR tyrosine kinase domain by stabilizing an optimal conformation of asymmetric TKD dimers. At the cell biological level, the Bill et al. model posited that the intracellular concentration of cytohesins was a relevant determinant of cellular responsiveness to EGFR ligands. The above model was extended to envisioning cytohesins as oncogenic modifiers of EGFR and potential therapeutic targets in tumors addicted to oncogenic EGFR signaling (Bill et al., 2010) .
Allosteric activation of the EGFR kinase is inhibited by activity-dependent binding of MIG6 (via its EBR, i.e., ErbB binding region) to an extended surface of the TKD that includes the peptide substrate-binding pocket and C-lobe distal region (Park et al., 2015; Zhang et al., 2007) . Because of their functional antagonism, we hypothesized that MIG6 and cytohesins could bind the EGFR TKD competitively. While pursuing this hypothesis, we did not observe significant regulation of EGFR activity by ARNO.
Bill et al. showed that ectopic expression of ARNO in H460 lung cancer cells increased EGFR autophosphorylation in a dose-dependent manner. While the Sec7 domain (carrying ARNO's GEF activity) was necessary and sufficient to upregulate EGFR catalytic activation, GEF activity per se was not required, because the GEF-dead E156K mutant was as efficient as wtARNO at increasing EGFR autophosphorylation (Bill et al., 2010) . In contrast, we found that graded overexpression of MYC-tagged ARNO in HeLa cells did not increase EGFR autophosphorylation in experiments that tested a range of EGF doses over different times of cell stimulation. MYC-ARNO E156K was likewise ineffective at enhancing EGFR autophosphorylation ( Figure 1A , 1B, S1A, and S1B). However, expression of MYC-MIG6 at levels comparable to those of MYC-ARNO induced robust suppression of EGFR autophosphorylation ( Figure 1B ), as reported (Anastasi et al., 2007) . Similar results were obtained in NR6-EGFR cells (Figures S1C-S1F). Finally, also in cells stimulated with EGF at 4 C, i.e., in absence of endocytosis, MYC-ARNO did not increase EGFR autophosphorylation, whereas MYC-MIG6 readily suppressed EGFR activation under these conditions (data not shown).
ARNO was proposed to enhance EGFR activation through its ability to bind to activated receptor dimers (Bill et al., 2010) , based on co-localization of ARNO with EGFR and detection of ARNO in anti-EGFR immunoprecipitates. Using nearly quantitative immunoprecipitation conditions, we detected neither MYC-ARNO immunoreactivity in anti-EGFR immunoprecipitates nor EGFR immunoreactivity in anti-MYC immunoprecipitates ( Figure 1C) . However, under similar conditions, we could readily detect co-immunoprecipitation between EGFR and MIG6 (Anastasi et al., 2007) ( Figure 1C ) and co-immunoprecipitation between ARNO and Connector Enhancer of KSR 1 (CNK1) (Lim et al., 2010) ( Figure S1G ). Following EGF stimulation, EGFR undergoes rapid endocytosis, trafficking to early endosomes and eventually sorting to late endosomes. We found that MYC-ARNO and EGFR immunoreactivity remained spatially separated in both resting and EGF-stimulated HeLa and NR6-EGFR derivatives (not shown). In contrast, we observed extensive relocalization of MYC-MIG6 onto endocytosed EGFR in EGF stimulated cells, which agreed with previous reports (Frosi et al., 2010) (not shown).
Key to the Bill et al. model was evidence showing that (1) ARNO bound directly to the EGFR intracellular domain (ICD) in cell-free assays; (2) purified recombinant ARNO (expressed as either full-length or isolated Sec7 domain) was capable of enhancing the rate of autophosphorylation of purified recombinant EGFR ICD. To test this in our laboratory, we used immobilized GST-fusion proteins as affinity reagents for the capture of soluble EGFR present in cell lysates. GST-MIG6 EBR and GST-GRB2 captured soluble EGFR over a 0.1-1 mM bait input and within a 2 hr incubation ( Figure 1D ). GST-ARNO pulldowns yielded EGFR immunoreactivity only when performed with the highest bait input (1 mM) and longest incubation times (i.e., >2 hr, Figure 1D) . Moreover, the amount of EGFR bound to GST-ARNO beads was markedly lower than that detected in GRB2 and MIG6 pulldown assays, irrespective of binding conditions ( Figure 1D ). In contrast, GST-ARNO captured soluble HA-CNK1 very efficiently ( Figure S1H ). In a second set of experiments, the ability of purified recombinant EGFR ICD (aa. 645-1186) to form a complex with either purified C and cell lysates probed with the indicated antibodies. Expression of EGFR and MYC-tagged proteins in lysates obtained from unstimulated cells is shown in Figure S1A. (B) The indicated HeLa cell derivatives were stimulated with escalating doses of EGF (ng/ml) for 5 min at 37 C and cell lysates probed with indicated antibodies. ARNO E156K was expressed at levels comparable to those of ARNO high . Expression of EGFR and MYC-tagged proteins in lysates obtained from unstimulated cells is shown in Figure S1B . See also Figures S1E and S1F. (C) Lysates from indicated HeLa cell derivatives stimulated with 50 ng/ml EGF for 5 min at 37 C were subjected to immunoprecipitation (IP) (top, anti-EGFR; bottom, anti-MYC) coupled to immunoblot analysis with indicated antibodies. Immunoblotted lysates correspond to 1/10 of input in IP reactions. See also Figure S1G . (D) Lysates from control or EGF-stimulated NR6-EGFR cells were incubated with indicated immobilized GST fusion proteins. Binding reactions were allowed to proceed for indicated time at 4 C using a fixed input of lysate and the indicated concentrations of GST baits. Bound EGFR was detected by anti-EGFR immunoblot (top); input baits were visualized by staining with Ponceau red (bottom). See also Figures S1H and S1I. (E) EGFR ICD (2 mM) was mixed with the indicated purified recombinant proteins (2-64 mM). Reactions were run for 90 s at 22 C. Samples were immunoblotted with anti-pTyr antibodies to detect phosphorylated EGFR (p-EGFR). Input proteins were visualized by Coomassie blue stain. See also Figure S1J. (legend continued on next page) recombinant ARNO Sec7 domain or purified recombinant MIG6 EBR was monitored by native polyacrylamide gel electrophoresis analysis (N-PAGE). This assay allowed for straightforward identification of EGFR:MIG6 complexes, as shown by a clear modification of the electrophoretic mobility of EGFR bands. Instead, addition of ARNO Sec7 did not appreciably modify the mobility of EGFR ICD ( Figure S1I ). Thus, our results indicated that ARNO bound the EGFR weakly and only in GST pulldown assays, possibly because immobilization on glutathione-agarose beads generates high local concentrations of GST baits, thus facilitating low-affinity interactions.
In order to test the ability of ARNO to enhance the catalytic activity of EGFR ICD in in vitro kinase reactions, we first verified that our preparation of purified WT EGFR ICD had a much greater catalytic activity in solution than its dimerization-defective V924R counterpart ( Figure S1J ). This ensured that our assay conditions reflected catalytic activation of soluble EGFR ICD via asymmetric TKD dimerization (Jura et al., 2009; Red Brewer et al., 2009 ). We did not observe enhanced EGFR ICD autophosphorylation when either flARNO or ARNO Sec7 domain were titrated into the in vitro kinase reaction over a 2-64 mM range ( Figure 1E ). Full-length ARNO induced a marginal increase of EGFR catalytic activity only in assays measuring phosphorylation of a synthetic substrate ( Figure 1F , top dataset). However, the significance of this effect is questionable, because it was small, could be observed only at high ARNO input and was not recapitulated by the Sec7 domain ( Figure 1F , top dataset). In contrast, both assays revealed strong suppression of EGFR catalytic activity by MIG6 EBR at 2-4 mM ( Figure 1E, F) . As a role in direct activation was not observed, the possibility that ARNO could enhance EGFR catalytic activity indirectly, i.e., by relieving the inhibitory constraint imposed by MIG6 EBR onto the EGFR TKD, was tested. To this end, we performed synthetic substrate phosphorylation assays in which the concentration of MIG6 EBR was kept constant, while ARNO (full-length or Sec7 domain) was titrated into the reaction over a range of concentrations. ARNO was not able to significantly rescue the EGFR ICD from MIG6-dependent inhibition ( Figure 1F, middle and bottom) . Comparable results were obtained in EGFR ICD in vitro autophosphorylation assays (data not shown).
Our experiments argue against ARNO being a robust modifier of EGFR catalytic activity. Although a certain degree of variability inherent in cell-based assays could account for some of the reported discrepancies, we have no definitive explanations for the substantial differences between the data reported by Bill et al. and ours. We note, however, that our results in cell-free assays were altogether consistent with those obtained in intact cells. That our data are robust is also indicated by control experiments that reproduced published data on (1) the ARNO/CNK1 physical interaction (Figures S1G and S1H) and (2) the ability of ectopic ARNO to remodel the actin cytoskeleton and relocate ARF1 from the Golgi to cytosol and plasmamembrane (data not shown). Consequently, we suggest that the assignment to ARNO, and by extension to all cytohesins, of a biologically significant role as enhancer of EGFR catalytic activity should be reconsidered. In addition, because Bill et al. proposed that cytohesins may act as oncogenic modifiers of ErbB RTKs signaling, we urge caution in (1) considering cytohesin expression as a surrogate biomarker of EGFR activation in human tumors lacking genomic EGFR alterations; (2) exploring pharmacological targeting of cytohesins as a strategy for curbing EGFR activation in tumors addicted to oncogenic EGFR signaling.
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